Ginkgo Bioworks DNA Government and defense — Concentration risk
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:ConcentrationRiskPercentage1.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's government and defense — concentration risk.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's government and defense — concentration risk?
- Ginkgo Bioworks (DNA) reported government and defense — concentration risk of 35% in Q1 2026.
- How has Ginkgo Bioworks's government and defense — concentration risk changed year-over-year?
- Ginkgo Bioworks's government and defense — concentration risk increased by 118.7% year-over-year, from 16% to 35%.
- What is the long-term trend for Ginkgo Bioworks's government and defense — concentration risk?
- Over 2 years (2021 to 2025), Ginkgo Bioworks's government and defense — concentration risk has grown at a 209.4% compound annual growth rate (CAGR), from 7% to 67%.
- What does government and defense — concentration risk mean?
- This metric measures the proportion of total segment revenue derived from government and defense contracts, highlighting the company's reliance on public sector funding. A high concentration indicates significant exposure to legislative budget cycles, policy shifts, and geopolitical priorities. Monitoring this ratio helps investors assess the stability and predictability of cash flows within the specific business unit.